Blood & Bone Marrow
High-performing professionals, competitive athletes, and active adults share a common goal when they come to see me: they want to heal, not just feel better temporarily. They want a treatment that addresses what is actually wrong rather than one that quiets the symptom while the underlying problem continues. Regenerative medicine represents the most meaningful step toward that goal that musculoskeletal medicine has taken in a generation, and for the right patient with the right diagnosis, it is changing what nonoperative care can realistically achieve.
THE BASICS
What Regenerative Medicine Is and How It Works
Regenerative medicine uses materials derived entirely from the patient's own body to stimulate tissue repair, reduce pathological inflammation, and restore function in damaged structures. The two most clinically validated therapies in this space are platelet-rich plasma and bone marrow aspirate concentrate. Platelet-rich plasma is prepared by drawing a small volume of the patient's blood, processing it to concentrate the platelet fraction, and delivering the resulting preparation under image guidance to the target tissue. Platelets are not simply clotting agents — they carry a dense payload of growth factors including PDGF, TGF-β, VEGF, and IGF-1 that initiate and regulate the tissue repair cascade. Bone marrow aspirate concentrate, harvested from the patient's iliac crest and processed to concentrate adult progenitor cells alongside a rich growth factor and bioactive protein milieu, provides a more potent biological stimulus for conditions involving more advanced degeneration — joints, intervertebral discs, and chronic tendon injuries where PRP alone may provide insufficient regenerative drive. Both therapies are autologous, meaning they are derived entirely from the patient's own biology, which eliminates concerns about rejection or foreign material response. Both are delivered as outpatient procedures under image guidance to ensure precise placement at the structural target.
The distinction between these therapies and corticosteroid injections is not merely one of degree — it is one of mechanism and intent. Corticosteroids suppress inflammation transiently and can provide meaningful short-term relief, but repeated use is associated with cartilage degradation, tendon weakening, and progressive tissue damage that can worsen the underlying condition over time. PRP and BMAC are designed to stimulate repair rather than suppress symptoms, which is why their benefit profile tends to strengthen beyond the three-month mark rather than fade.
CLINICAL EVIDENCE
What the Research Supports
The evidence base for regenerative medicine in musculoskeletal conditions has matured considerably over the past decade. PRP has demonstrated superiority over corticosteroid injection for lateral epicondylitis, patellar tendinopathy, and knee osteoarthritis at medium and long-term follow-up in multiple randomized controlled trials. For knee osteoarthritis specifically, PRP produces superior pain and function outcomes compared to both corticosteroid and hyaluronic acid injections at six and twelve months in high-quality comparative studies. Intradiscal PRP for discogenic low back pain, including work from the Hospital for Special Surgery, has shown meaningful improvements in pain and function at eight weeks with durability extending to one year and beyond. BMAC carries growing evidence for joint applications where the degenerative burden exceeds what PRP can adequately address, with outcomes data supporting its use in moderate to advanced osteoarthritis and chronic tendon conditions. The consistent theme across this literature is that precision of both diagnosis and delivery determines outcome — the biological potential of these therapies is realized only when the right preparation reaches the right tissue in a patient whose clinical picture genuinely warrants a regenerative approach.
A CRITICAL NOTE ON UNPROVEN PRODUCTS
The growth of regenerative medicine has unfortunately been accompanied by a parallel growth in poorly regulated and scientifically unsupported products being marketed to patients and administered by providers who are not following FDA guidelines or evidence-based standards. Commercial allografts derived from umbilical cord blood, Wharton's jelly, and amniotic tissue are heavily marketed as regenerative treatments despite peer-reviewed evidence demonstrating that these products contain no viable cells and fall substantially short of true regenerative biological activity. A published study — Colony Forming Potential and Protein Composition of Commercial Umbilical Cord Allograft Products in Comparison With Autologous Orthobiologics — confirmed this directly, finding that commercial allografts do not meet the biological standard that autologous preparations achieve. In Florida, legislative proposals including Senate Bill 1768 have raised concerns about legitimizing these unproven products in a regulatory environment that already struggles to protect patients from misleading claims. I use only autologous biologics — therapies derived from the patient's own body — prepared and delivered according to the published evidence and current FDA standards. Patients deserve to know the difference, and they deserve a physician who will be honest about it.
PATIENT SELECTION
Who Benefits and What the Evaluation Involves
The conditions I treat most commonly with regenerative medicine include chronic tendinopathies of the lateral elbow, rotator cuff, Achilles tendon, and patellar tendon; mild to moderate osteoarthritis of the knee, hip, and shoulder; sacroiliac joint dysfunction; labral and meniscal pathology where surgical repair is not indicated; discogenic low back pain that has failed conservative management; and post-injury or post-surgical recovery where tissue healing has plateaued. Before any regenerative procedure is recommended, I perform a comprehensive evaluation including detailed physical examination, advanced imaging review, and diagnostic blocks where appropriate to confirm the pain generator. This precision-first model ensures that the therapy delivered corresponds to the diagnosis confirmed — not to the symptom reported. Delivering a regenerative treatment to the wrong structure produces no benefit regardless of how potent the biologic is, and the evaluation is where the outcome is largely determined.
All procedures are performed under image guidance — ultrasound, fluoroscopy, or both depending on the target — to ensure accurate delivery. Precision of placement is not incidental to the procedure. It is a primary determinant of whether the biology works.
FOR REFERRING CLINICIANS
Regenerative medicine is most valuable in the clinical context where conventional injectables have provided inadequate or diminishing benefit, where the patient is seeking to avoid or delay surgery, or where the evidence supports a biologic therapy as the superior long-term option for a specific diagnosis. I offer comprehensive evaluation to confirm candidacy, autologous PRP and BMAC procedures for tendon, joint, and spinal indications, and detailed documentation of findings, technique, and follow-up plan back to the referring provider. I welcome direct physician-to-physician consultation.
PERSPECTIVE
A Note on Doing Regenerative Medicine Right
The promise of regenerative medicine is real, and so is the responsibility that comes with it. These are powerful biological tools that produce meaningful outcomes when applied with diagnostic precision, appropriate patient selection, and preparations that meet the biological standard the evidence demands. They also produce disappointing outcomes — and patient harm — when used indiscriminately, when unproven products are substituted for validated autologous therapies, or when the diagnosis driving the treatment has not been rigorously confirmed. My approach to regenerative medicine is the same as my approach to every intervention I offer: the decision to treat must be grounded in a clear understanding of what is wrong, what the evidence shows about how to address it, and what the patient's realistic expectations should be. For the patient who fits that profile — the right diagnosis, the right preparation, the right delivery — regenerative medicine offers something that very few other nonoperative options can match: the genuine possibility of tissue-level improvement and durable relief. That is worth pursuing, and worth doing carefully.
DISCLOSURE & REFERENCES
This article is for educational purposes and reflects clinical experience and interpretation of published literature. It is not a substitute for individualized medical evaluation. Key references: Mishra AK et al. 2014 (PRP for lateral epicondylitis, Am J Sports Med); Filardo G et al. 2015 (PRP for knee OA, Knee Surg Sports Traumatol Arthrosc); Tuakli-Wosornu YA et al. 2016 (intradiscal PRP, PM&R); Centeno CJ et al. 2011 (BMAC for musculoskeletal conditions, Pain Physician); Shapiro SA et al. 2017 (BMAC for knee OA, Am J Sports Med); Becktell L et al. 2022 (colony forming potential of commercial allografts vs autologous orthobiologics, Orthop J Sports Med).
ABOUT THE AUTHOR
Dr. Mahajer is a double board-certified physiatrist and sports medicine physician, fellowship-trained in Interventional Spine & Sports Medicine at the Icahn School of Medicine at Mount Sinai. He is an Assistant Professor of Neuroscience at FIU Herbert Wertheim College of Medicine. He is the Immediate Past President of the American Osteopathic College of Physical Medicine and Rehabilitation (AOCPMR), holds medical licenses in Florida, New York, and California, and has been recognized as a Top Physiatrist and Top Doctor in both Florida and New York.
